Pharmafile Logo
Pharmafocus logo
Advanced Search

Bristol Myers Squibb’s deucravacitinib beats Amgen’s Otezla to meet main goal in plaque psoriasis

November 4, 2020
Research and Development BMS, deucravacitinib, plaque psoriasis

Bristol Myers Squibb has unveiled new Phase 3 data showing that its oral, selective tyrosine kinase 2 (TYK2) inhibitor deucravacitinib …

News
regeneron

Regeneron halts Phase 1 study into ultra-rare disease due to patient deaths

November 3, 2020
Manufacturing and Production, Research and Development Regeneron, clinical trials, garetosmab, pharma

Regeneron has slammed the brakes on its Phase 1 trial of garetosmab in the treatment of the ultra-rare condition fibrodysplasia …

News

UCB Pharma’s bimekizumab improves skin clearance over Humira in plaque psoriasis

November 3, 2020
Manufacturing and Production, Research and Development UCB Pharma, bimekizumab, pharma

In recent Phase 3 study data presented European Academy of Dermatology and Venereology Congress last weekend, UCB Pharma reported that …

News
covid_cell_1

T-cells respond to COVID-19 six months after infection

November 3, 2020
Manufacturing and Production

There is evidence that human T-cells can respond to coronavirus six months after the body is initially infected, according to …

News
800px-laboratoires_arkopharma_-_chaine_de_conditionnement_remplissage_piluliers_1

Novavax to expand Maryland facility to support global vaccine development

November 3, 2020
Manufacturing and Production

Novavax has announced that it plans to expand its Maryland campus to facilitate the company’s growth as it develops its …

News
tt

How the US election could affect the pharmaceutical industry

November 3, 2020
Manufacturing and Production

The US is one of the most lucrative markets for the pharmaceutical industry. This is a country where a lack of …

News
800px-pfizer_finland_hq_february_13_2009_2

Pfizer announces €300m investment in Irish manufacturing sites

November 2, 2020
Sales and Marketing

Pfizer is set to invest €300 million in its three Irish manufacturing sites in Ringaskiddy, Dublin and Kildare.  The investment …

News
madrid_-_johnson__johnson_1

Johnson & Johnson to begin testing COVID-19 vaccine on adolescent patients

November 2, 2020
Sales and Marketing

Johnson & Johnson plans to start testing its COVID-19 vaccine candidate in adolescents between the age of 12 and 18.  …

News
nauchnyy_seminar

Pharmasyntez asks Russian Government for permission to produce generic version of remdesivir for COVID-19

November 2, 2020
Sales and Marketing

Russian drug firm Pharmasyntez has asked the government for permission to produce a generic version of Gilead’s remdesivir without a …

News
shutterstock_273326141

Sanofi angles to buy Kiadis for €308 million

November 2, 2020
Sales and Marketing Sanofi, kiadis, pharma

Sanofi has announced it is poised to buy out Amsterdam-based biopharma firm Kiadis in an all-cash public offer of €308 …

News
dermatitis2015_-_copy

LEO Pharma’s delgocitinib hits main goals in moderate-to-severe chronic hand eczema

November 2, 2020
Research and Development, Sales and Marketing LEO Pharma, eczema, pharma

LEO Pharma has revealed new Phase 2b at the European Academy of Dermatology and Venereology (EADV) Virtual 2020 Virtual Congress …

News
parag_agarwal_-17485

Parag Agarwal appointed as Dr Reddy’s Laboratories Chief Financial Officer

October 30, 2020
Sales and Marketing

Dr Reddy’s Laboratories has appointed Parag Agarwal has the company’s new Chief Financial Officer. Parag has a career that spans …

Appointment
nice_new_london_office_internal_3_web

NICE recommends Novo’s liraglutide for management of obesity and non-diabetic hyperglycaemia

October 30, 2020
Medical Communications, Sales and Marketing NICE, Novo Nordisk, liraglutide

Novo Nordisk’s pre-filled injection Saxenda (liraglutide) has received the backing of drug watchdog NICE, meaning it will now be made …

News
shutterstock_87495637

AstraZeneca jettisons two heart drugs to Cheplapharm in $400m deal

October 30, 2020
Manufacturing and Production, Medical Communications, Sales and Marketing AstraZeneca, Cheplapharm

AstraZeneca is set to sell the rights to its AT1 subtype angiotensin II receptor antagonist Atacand (candesartan cilexetil) and Atacand …

News
800px-european_commission_flags_1

EU approves Zejula as a first-line monotherapy maintenance treatment in advanced ovarian cancer

October 30, 2020
Medical Communications

The European Commission has approved GlaxoSmithKline’s Zeljula as a first line monotherapy maintenance treatment for adult patients with ovarian cancer …

News
49798220211_23b94b0fb8_b

New study suggests UK Government’s ‘Eat Out to Help Out’ scheme increased coronavirus infection rates

October 30, 2020
Medical Communications

The Eat Out to Help Out scheme contributed to a significant rise in new coronavirus cases according to a study …

News
top_10_image_2

Top Ten most popular articles on Pharmafile.com this week

October 30, 2020
Medical Communications

The top ten news stories this week focus on COVID-19 studies, as new research has found that over 80% of …

News
heinz-woodward-front1

David Woodward joins GAMA Healthcare as Board Business Advisory Consultant and CEO Mentor

October 29, 2020
Business Services

GAMA Healthcare have announced that David Woodward has been brought on as Board Business Advisory Consultant and CEO Mentor. Woodward …

Appointment
europe-1395916_640

European Commission greenlights Insmed’s Arikayce for nontuberculous mycobacterial lung infections

October 29, 2020
Sales and Marketing Arikayce, EU, lungs, pharma

The European Commission (EC) has given approval to Insmed Incorporated’s Arikayce (liposomal 590mg nebuliser dispersion) for the treatment of nontuberculous …

News
tumour-infiltrating_lymphocytes_-_2_--_very_high_mag

NICE says test people with womb cancer for Lynch syndrome

October 29, 2020
Medical Communications

New guidance from the National Institute of Health and Care Excellence says that women with womb cancer should be tested …

News
The Gateway to Local Adoption Series

Latest content

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026

PSI appoints David Allen as Country Manager for Canada

January 22, 2026

Qureight appoints Steven Bishop as Chief Medical Officer

January 21, 2026

Pierre Fabre Laboratories and Iktos announce oncology collaboration

January 21, 2026

Qureight appoints Rebecca Simmons as Chief Operating Officer

January 20, 2026